Fabry Cardiomyopathy: Current Treatment and Future Options

Area of Science:

• Genetics and rare diseases
• Cardiology
• Lysosomal storage disorders

Background:

• Fabry disease is an X-linked lysosomal storage disorder caused by alpha-galactosidase A (GLA) gene mutations.
• Deficient GLA activity leads to globotriaosylceramide (GL3) accumulation, affecting organs like the heart, kidneys, and nervous system.
• Cardiac involvement, manifesting as left ventricular hypertrophy, is a common complication.

Purpose of the Study:

• To review current and potential future therapeutic strategies for Fabry cardiomyopathy.
• To emphasize the importance of early intervention in managing cardiac manifestations.

Main Methods:

• Literature review of current treatments (enzyme replacement, chaperone therapy).
• Exploration of emerging therapies, including gene therapy.
• Focus on the impact of treatment timing on myocardial fibrosis and function.

Main Results:

• Standard treatments include enzyme replacement and chaperone therapy.
• Early treatment initiation is crucial to prevent myocardial fibrosis and preserve cardiac function.
• Gene therapy and other novel approaches are under development for future treatment.

Conclusions:

• Effective management of Fabry cardiomyopathy requires timely intervention.
• Future therapies, such as gene therapy, hold promise for improved long-term outcomes.